Our study describes the immune phenotypes associated with inhibiting SHP2 in cancer cells and the tumor microenvironment, supporting the promise of therapeutically inhibiting SHP2 activity in patients with molecularly and phenotypically diverse malignancies. This evidence concerns the gene PTPN11 and cancer.